Background: Treatment of Cervical cancer includes a combination of external beam radiotherapy (EBRT) with intracavitary brachytherapy (ICBT). ICBT helps to boost radiation dose to primary disease. Organs like rectum, ...Background: Treatment of Cervical cancer includes a combination of external beam radiotherapy (EBRT) with intracavitary brachytherapy (ICBT). ICBT helps to boost radiation dose to primary disease. Organs like rectum, bladder, sigmoid and small bowel lie close to the cervix region and these organs receive dose from EBRT as well as ICBT and we want to know the dose to these organ at risk (OAR). Materials & Methods: Dosimetric details of 174 ICBT applications done in 58 patients were retrospectively analysed. All patients received EBRT dose of 50.4 Gy in 28 fractions. All patients had ICBT, three sessions with 7 Gy prescribed to point A. Dosimetric data including dose to right and left point A and dose to OARs were recorded from Oncentra Planning System. Results: Mean dose to point A on right side was 6.89 Gy and left side was 6.91 Gy. Mean D2cc dose to rectum, bladder, sigmoid and small bowel was 3.5 Gy, 5.25 Gy, 4.75 Gy and 4.2 Gy respectively. Mean EQD2 dose combining EBRT and ICBT in point A was 78.7 Gy on right side and 79 Gy on left side. Mean EQD2 doses to D2cc of rectum, bladder, sigmoid and small bowel was 62 Gy, 74.4 Gy, 70.5 Gy and 66.5 Gy respectively. Conclusion: From the results of this dosimetric study it is evident that OARs like rectum, sigmoid, bladder & bowel are receiving only acceptable doses of radiation using point A prescribed CT based ICBT planning. Hence with regards to OAR doses, CT based ICBT planning with dose prescribed to point A is a feasible option.展开更多
[目的]分析中国基于人群的上消化道癌筛查项目中高危人群参加内镜筛查的依从率,为制定干预措施提供依据。[方法]系统检索英文数据库(Web of Science、PubMed和Embase)和中文数据库(中国知网、万方和维普)中有关中国人群的上消化道癌内...[目的]分析中国基于人群的上消化道癌筛查项目中高危人群参加内镜筛查的依从率,为制定干预措施提供依据。[方法]系统检索英文数据库(Web of Science、PubMed和Embase)和中文数据库(中国知网、万方和维普)中有关中国人群的上消化道癌内镜筛查依从率的文献,考虑区域、年龄、性别和项目的差异进行亚组分析,并进行敏感性分析和发表偏倚的评价。[结果]共纳入34篇文献,包含16个行政区766039名研究对象。中国上消化道癌高危人群的内镜筛查依从率为35.8%(95%CI:31.0%~40.5%)。亚组分析显示,农村地区(44.3%)内镜筛查依从率高于城市地区(32.5%)(P<0.05);男性依从率为37.9%,女性为42.9%(P>0.05);50~59岁年龄组依从率为41.6%,40~49岁年龄组为37.5%(P>0.05);淮河流域癌症早诊早治项目的依从率高于城市癌症早诊早治项目的依从率(P<0.05)。农村地区男性依从率(41.7%)低于女性(49.4%)(P<0.05),依从率随年龄的增长而增长;城市地区50~59岁年龄组依从率为38.9%,60~74岁年龄组为30.7%,差异无统计学意义(P>0.05)。通过敏感性分析剔除样本量较小的文献之后,Meta分析的结果稍有改变。[结论]中国上消化道癌高危人群内镜筛查依从率较低,且存在明显的地区与性别差异,需对男性及城市地区采取针对性措施,同时提高筛查提供方的能力建设,以提高公众的筛查意识和参与度。展开更多
Background： Hebei province is located in North of China with of approximately 6% of whole national population. It is known as a high-risk area for esophageal cancer in China and worldwide. The aim of our study was to...Background： Hebei province is located in North of China with of approximately 6% of whole national population. It is known as a high-risk area for esophageal cancer in China and worldwide. The aim of our study was to estimate the esophageal cancer burden and trend in Hebei Province. Methods： Eight cancer registries in Hebei Province submitted cancer registry data to the Hebei Provincial Cancer Registry Center. All data were qualified and compiled for cancer statistics in 2011. The pooled data were stratified by gender and age group （0, 1-4, 5-9, 10-14...80＋）. Incidence and mortality rates were age-standardized to World Segi＇s population standard and expressed per 100,000 persons. In addition, proportions and cumulative incidence/mortality rates for esophageal cancer were calculated. Esophageal cancer mortality data during the periods 1973-1975, 1990-1992, and 2004-2005 were extracted from the national death surveys. Mortality and incidence rate data from Cixian and Shexian were obtained from population-based cancer registries in each county. Results： The estimated number of newly diagnosed esophageal cancer cases and deaths in 2011 in Hebei Province was 24,318 and 18,226, respectively. The crude incidence rate of esophageal cancer was 33.37/100,000 （males, 42.18/100,000 and females, 24.31/100,000）. The age-standardized rate by world standard population （ASRW） was 28.09/100,000, ranking third among all cancers. The esophageal cancer mortality rate was 25.01/100,000 （males, 31.40/100,000 and females, 18.45/100,000）, ranking third in deaths among all cancers. The mortality rates of esophageal cancer displayed a significant decreasing trend in Hebei Province from 1973-1975 （ASRW =48.69/100,000） to 2004-2005 （ASRW =28.02/100,000）, with a decreased rate of 42.45%. In Cixian, the incidence of esophageal cancer decreased from 250.76/100,000 to 106.74/100,000 in males and from 153.86/100,000 to 75.41/100,000 in females, with annual percentage changes （APC） of 2.13 and 2.16, while the mortality rates declined with an APC of 2.46 for males and 3.10 for females from 1988 to 2011. In Shexian, the incidence rate decreased from 116.90/100,000 to 74.12/100,000 in males and from 46.98/100,000 to 40.64/100,000 in females, while the mortality rates declined, with an APC of 4.89 in males from 2003 to 2011. Conclusions： Although the incidence and mortality rates of esophageal cancer remain high, an obvious decreasing trend has been observed in Hebei Province, as well as in high-risk regions, such as Cixian and Shexian, over the past 40 years.展开更多
目的分析南京地区人群高危型人乳头状瘤病毒(high-risk human papillomavirus,HR-HPV)感染情况以及检测结果基因分型的分布。方法收集2019年1月至2023年5月就诊于南京医科大学第一附属医院行HPV检测的3048例患者作为研究对象,其中包括2...目的分析南京地区人群高危型人乳头状瘤病毒(high-risk human papillomavirus,HR-HPV)感染情况以及检测结果基因分型的分布。方法收集2019年1月至2023年5月就诊于南京医科大学第一附属医院行HPV检测的3048例患者作为研究对象,其中包括2781名女性和267名男性。采用实时荧光PCR技术检测HR-HPV的基因型,分析HPV感染率、感染亚型及不同年龄、性别患者的基因型分布特点。结果3048例患者中,共有598例HPV阳性感染者,总阳性率为19.62%。HPV感染率前5位由高到低依次是52型(191,6.27%)、58型(114,3.74%)、16型(90,2.95%)、51型(54,1.77%)和68型(51,1.67%)。阳性患者中,男性51(8.53%)例,女性547(91.47%)例。其中,女性阳性占比较高的3种亚型为:52型(175,29.26%)、58型(107,17.89%)和16型(82,13.71%);男性阳性占比较高的3种亚型为52型(16,2.68%)、18型(9,1.51%)和16型(8,1.34%)。患者年龄分布在4~81岁之间,中位年龄为38岁。根据患者年龄分成6个年龄组(≤20岁、21~30岁、31~40岁、41~50岁、51~60岁和>60岁),各年龄组间感染阳性率差异有统计学意义(χ^(2)=30.425,P<0.05),31~40岁组最高达36.46%(218/598)。分析不同年龄段阳性检出率,≤20岁年龄段人群的检出率最高,为40.63%(13/32)。HPV感染者中,单一型别感染例数占比较高为74.58%(446/598)。结论南京地区HR-HPV感染亚型以52型、58型、16型最常见,其次为51型和68型。研究HR-HPV基因型分布特点为南京地区人群HR-HPV感染及防治提供依据,推荐适龄男性及女性接种HPV疫苗、加强高危人群的HPV筛查。展开更多
文摘Background: Treatment of Cervical cancer includes a combination of external beam radiotherapy (EBRT) with intracavitary brachytherapy (ICBT). ICBT helps to boost radiation dose to primary disease. Organs like rectum, bladder, sigmoid and small bowel lie close to the cervix region and these organs receive dose from EBRT as well as ICBT and we want to know the dose to these organ at risk (OAR). Materials & Methods: Dosimetric details of 174 ICBT applications done in 58 patients were retrospectively analysed. All patients received EBRT dose of 50.4 Gy in 28 fractions. All patients had ICBT, three sessions with 7 Gy prescribed to point A. Dosimetric data including dose to right and left point A and dose to OARs were recorded from Oncentra Planning System. Results: Mean dose to point A on right side was 6.89 Gy and left side was 6.91 Gy. Mean D2cc dose to rectum, bladder, sigmoid and small bowel was 3.5 Gy, 5.25 Gy, 4.75 Gy and 4.2 Gy respectively. Mean EQD2 dose combining EBRT and ICBT in point A was 78.7 Gy on right side and 79 Gy on left side. Mean EQD2 doses to D2cc of rectum, bladder, sigmoid and small bowel was 62 Gy, 74.4 Gy, 70.5 Gy and 66.5 Gy respectively. Conclusion: From the results of this dosimetric study it is evident that OARs like rectum, sigmoid, bladder & bowel are receiving only acceptable doses of radiation using point A prescribed CT based ICBT planning. Hence with regards to OAR doses, CT based ICBT planning with dose prescribed to point A is a feasible option.
文摘[目的]分析中国基于人群的上消化道癌筛查项目中高危人群参加内镜筛查的依从率,为制定干预措施提供依据。[方法]系统检索英文数据库(Web of Science、PubMed和Embase)和中文数据库(中国知网、万方和维普)中有关中国人群的上消化道癌内镜筛查依从率的文献,考虑区域、年龄、性别和项目的差异进行亚组分析,并进行敏感性分析和发表偏倚的评价。[结果]共纳入34篇文献,包含16个行政区766039名研究对象。中国上消化道癌高危人群的内镜筛查依从率为35.8%(95%CI:31.0%~40.5%)。亚组分析显示,农村地区(44.3%)内镜筛查依从率高于城市地区(32.5%)(P<0.05);男性依从率为37.9%,女性为42.9%(P>0.05);50~59岁年龄组依从率为41.6%,40~49岁年龄组为37.5%(P>0.05);淮河流域癌症早诊早治项目的依从率高于城市癌症早诊早治项目的依从率(P<0.05)。农村地区男性依从率(41.7%)低于女性(49.4%)(P<0.05),依从率随年龄的增长而增长;城市地区50~59岁年龄组依从率为38.9%,60~74岁年龄组为30.7%,差异无统计学意义(P>0.05)。通过敏感性分析剔除样本量较小的文献之后,Meta分析的结果稍有改变。[结论]中国上消化道癌高危人群内镜筛查依从率较低,且存在明显的地区与性别差异,需对男性及城市地区采取针对性措施,同时提高筛查提供方的能力建设,以提高公众的筛查意识和参与度。
基金supported by grants from the National Natural Scientific Foundation of China(81272682)the National Natural Scientific Foundation of Hebei Province(C2011206058)financial department of Hebei Province[No.(2012)2056]
文摘Background： Hebei province is located in North of China with of approximately 6% of whole national population. It is known as a high-risk area for esophageal cancer in China and worldwide. The aim of our study was to estimate the esophageal cancer burden and trend in Hebei Province. Methods： Eight cancer registries in Hebei Province submitted cancer registry data to the Hebei Provincial Cancer Registry Center. All data were qualified and compiled for cancer statistics in 2011. The pooled data were stratified by gender and age group （0, 1-4, 5-9, 10-14...80＋）. Incidence and mortality rates were age-standardized to World Segi＇s population standard and expressed per 100,000 persons. In addition, proportions and cumulative incidence/mortality rates for esophageal cancer were calculated. Esophageal cancer mortality data during the periods 1973-1975, 1990-1992, and 2004-2005 were extracted from the national death surveys. Mortality and incidence rate data from Cixian and Shexian were obtained from population-based cancer registries in each county. Results： The estimated number of newly diagnosed esophageal cancer cases and deaths in 2011 in Hebei Province was 24,318 and 18,226, respectively. The crude incidence rate of esophageal cancer was 33.37/100,000 （males, 42.18/100,000 and females, 24.31/100,000）. The age-standardized rate by world standard population （ASRW） was 28.09/100,000, ranking third among all cancers. The esophageal cancer mortality rate was 25.01/100,000 （males, 31.40/100,000 and females, 18.45/100,000）, ranking third in deaths among all cancers. The mortality rates of esophageal cancer displayed a significant decreasing trend in Hebei Province from 1973-1975 （ASRW =48.69/100,000） to 2004-2005 （ASRW =28.02/100,000）, with a decreased rate of 42.45%. In Cixian, the incidence of esophageal cancer decreased from 250.76/100,000 to 106.74/100,000 in males and from 153.86/100,000 to 75.41/100,000 in females, with annual percentage changes （APC） of 2.13 and 2.16, while the mortality rates declined with an APC of 2.46 for males and 3.10 for females from 1988 to 2011. In Shexian, the incidence rate decreased from 116.90/100,000 to 74.12/100,000 in males and from 46.98/100,000 to 40.64/100,000 in females, while the mortality rates declined, with an APC of 4.89 in males from 2003 to 2011. Conclusions： Although the incidence and mortality rates of esophageal cancer remain high, an obvious decreasing trend has been observed in Hebei Province, as well as in high-risk regions, such as Cixian and Shexian, over the past 40 years.
文摘目的分析南京地区人群高危型人乳头状瘤病毒(high-risk human papillomavirus,HR-HPV)感染情况以及检测结果基因分型的分布。方法收集2019年1月至2023年5月就诊于南京医科大学第一附属医院行HPV检测的3048例患者作为研究对象,其中包括2781名女性和267名男性。采用实时荧光PCR技术检测HR-HPV的基因型,分析HPV感染率、感染亚型及不同年龄、性别患者的基因型分布特点。结果3048例患者中,共有598例HPV阳性感染者,总阳性率为19.62%。HPV感染率前5位由高到低依次是52型(191,6.27%)、58型(114,3.74%)、16型(90,2.95%)、51型(54,1.77%)和68型(51,1.67%)。阳性患者中,男性51(8.53%)例,女性547(91.47%)例。其中,女性阳性占比较高的3种亚型为:52型(175,29.26%)、58型(107,17.89%)和16型(82,13.71%);男性阳性占比较高的3种亚型为52型(16,2.68%)、18型(9,1.51%)和16型(8,1.34%)。患者年龄分布在4~81岁之间,中位年龄为38岁。根据患者年龄分成6个年龄组(≤20岁、21~30岁、31~40岁、41~50岁、51~60岁和>60岁),各年龄组间感染阳性率差异有统计学意义(χ^(2)=30.425,P<0.05),31~40岁组最高达36.46%(218/598)。分析不同年龄段阳性检出率,≤20岁年龄段人群的检出率最高,为40.63%(13/32)。HPV感染者中,单一型别感染例数占比较高为74.58%(446/598)。结论南京地区HR-HPV感染亚型以52型、58型、16型最常见,其次为51型和68型。研究HR-HPV基因型分布特点为南京地区人群HR-HPV感染及防治提供依据,推荐适龄男性及女性接种HPV疫苗、加强高危人群的HPV筛查。
